Based on these backgrounds, co-expression of both IL-34 and M-CSF - naturally or induced under therapeutic conditions - may characterize malignancies with enhanced aggression and has an impact on the clinical outcome of cancer therapy. The gene discussed is CSF1; the disease is cancer.